Hsbc Holdings PLC Invests $49,000 in TScan Therapeutics, Inc. $TCRX

Hsbc Holdings PLC bought a new position in TScan Therapeutics, Inc. (NASDAQ:TCRX) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 35,042 shares of the company’s stock, valued at approximately $49,000. Hsbc Holdings PLC owned about 0.06% of TScan Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Wells Fargo & Company MN boosted its stake in shares of TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after buying an additional 5,694 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of TScan Therapeutics by 5.2% in the fourth quarter. Wellington Management Group LLP now owns 132,895 shares of the company’s stock worth $404,000 after buying an additional 6,550 shares during the last quarter. Woodline Partners LP boosted its stake in shares of TScan Therapeutics by 6.7% in the fourth quarter. Woodline Partners LP now owns 115,866 shares of the company’s stock worth $352,000 after buying an additional 7,282 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of TScan Therapeutics by 0.9% in the first quarter. Aberdeen Group plc now owns 891,448 shares of the company’s stock worth $1,230,000 after buying an additional 7,744 shares during the last quarter. Finally, Barclays PLC boosted its position in TScan Therapeutics by 16.3% during the fourth quarter. Barclays PLC now owns 67,508 shares of the company’s stock worth $206,000 after purchasing an additional 9,441 shares in the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Wall Street Zen upgraded TScan Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 12th. Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and an average price target of $7.80.

TScan Therapeutics Stock Performance

NASDAQ TCRX opened at $1.91 on Monday. The company has a market cap of $108.39 million, a PE ratio of -1.75 and a beta of 1.00. The stock’s 50 day simple moving average is $1.76 and its 200-day simple moving average is $1.61. TScan Therapeutics, Inc. has a 1-year low of $1.02 and a 1-year high of $6.23. The company has a debt-to-equity ratio of 0.18, a current ratio of 7.06 and a quick ratio of 7.06.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Tuesday, August 12th. The company reported ($0.28) earnings per share for the quarter, meeting the consensus estimate of ($0.28). The business had revenue of $3.08 million for the quarter, compared to the consensus estimate of $1.31 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%. As a group, equities research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.